Update 1 van 1NieuwsteDag 1
Four Drugs, One Courtroom: Novo Nordisk Takes Eli Lilly to Trial Over GLP-1 Ads
A New Jersey federal complaint says Lilly's Zepbound and Mounjaro ads stack the dosing deck against Wegovy and Ozempic. The market they share is reshaping the industry.
Wat we eerst wisten
- Novo Nordisk filed a false-advertising complaint against Eli Lilly in New Jersey federal court on July 21, 2026.
- Novo is seeking a permanent injunction requiring Lilly to pull the comparative advertising.
- The core allegation is that Lilly's ads compare top-dose Zepbound and Mounjaro to lower-dose Wegovy and Ozempic, omitting newer higher-dose Novo formulations.
Toen nog open
- Any verbatim Lilly on-the-record statement beyond the general "truthful and based on the best available scientific evidence" framing. The source file does not include one.
- How the court will treat the question of which doses are properly comparable, and which clinical trials it considers current.
- Whether the case produces a settlement, a ruling on the injunction, or a long discovery fight.
Waar we op zouden letten
- Whether Lilly pulls, modifies, or continues the disputed advertising while the case is pending.
- Whether Novo's filings prompt parallel actions, including any Lanham Act or state-level complaints beyond New Jersey.
- How the dosing-comparison fight reshapes comparative advertising across the rest of the GLP-1 category.